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ABSTRACT:
Purpose: The signal transducer and activator of transcription 3 (STAT3) is a 
key molecular hub of tumorigenesis and immune suppression. The expression 
of phosphorylated STAT3 (p-STAT3) has been shown to be higher in melanoma 
metastasis to the central nervous system (CNS) relative to distant metastasis in the 
rest of the body (systemic). We sought to determine whether the increased expression 
of p-STAT3 in non-CNS systemic melanoma metastasis is associated with an increased 
risk of developing CNS metastasis and is a negative prognostic factor for overall 
survival time. 
Methods: We retrospectively identified 299 patients with stage IV melanoma. In a 
tissue microarray of systemic non-CNS metastasis specimens from these patients, we 
used immunohistochemical analysis to measure the percentage of cells with p-STAT3 
expression and Kaplan–Meier survival estimates to analyze the association of p-STAT3 
expression with median survival time, time to first CNS metastasis, and development 
of CNS metastasis. 
Results: Lung metastases exhibited the highest level of p-STAT3 expression while 
spleen lesions had the lowest. The p-STAT3 expression was not associated with an 
increased risk of developing CNS metastasis or time to CNS metastasis. However, 
p-STAT3 expression was a negative prognostic factor for overall survival time in 
patients that did not develop CNS metastasis. 
Conclusions: Stage IV melanoma patients without CNS metastasis treated with 
p-STAT3 inhibitors in efficacy studies should be stratified based on tumor expression 
of p-STAT3; however since p-STAT3 expression is not associated with the risk of CNS 
disease, increased MRI surveillance of the brain is not likely necessary.
INTRODUCTION
Although very early stage melanoma has an 
excellent prognosis, with 10-year survival rates as high 
as 95%, once distant metastases develop, survival drops 
to 8-20% at 10 years [1]. Unfortunately, melanoma has 
a high propensity to metastasize to the central nervous 
system (CNS). It is the third most common cause of brain 
metastases, after lung cancer and breast cancer [2]. In fact, 
over their lifetime, CNS involvement is reported in 46% of 
melanoma patients [3, 4]. The incidence of CNS metastasis 
in melanoma patients ranges from 50% to 70% in autopsy Oncotarget 2012; 3:  336-344 337 www.impactjournals.com/oncotarget
series [5, 6]. Once melanoma has metastasized to the brain, 
the prognosis is dismal despite multi-modality therapy. 
CNS recurrence is often the first site of progression seen 
in up to 25% of responsive patients [7] and the median 
survival time in melanoma is approximately 5 months in 
large published series [8]. As many as 70% of patients 
who develop CNS metastases have multiple symptomatic 
lesions  and hence are often ineligible for clinical trials 
[9]. As such, the determination of the factors leading to the 
development of distant melanoma metastases, especially 
CNS metastases, and the elucidation of potential agents 
to block the effects of these factors is an area of intense 
investigation. 
A key transcription factor, STAT3, has been shown 
to drive the fundamental components of tumorigenesis 
and metastasis by preventing apoptosis (by increasing 
expression of survivin, BCL-XL, and MCL1) and 
enhancing proliferation (by increasing expression of c-Myc 
and cyclin D1/D2) [10], angiogenesis (by increasing 
expression of VEGF and hypoxia-inducible factor-1α), 
and metastasis (by increasing expression of MMP-2 and 
MMP-9) [11, 12]. Growth factors and cytokines, including 
interleukin (IL)-6, can activate STAT3 by phosphorylating 
the tyrosine residue in the STAT3 transactivation domain 
[13]. The p-STAT3 then translocates into the nucleus and 
induces the expression of a variety of target genes. STAT3 
is constitutively overexpressed in many different cancers; 
in melanoma, 81% of CNS metastases express activated 
STAT3 [14]. Preclinical studies using decoy antisense 
STAT3 oligonucleotides, dominant-negative vectors, 
and small-molecule inhibitors have provided convincing 
evidence that STAT3 is highly relevant to the growth 
and survival of many tumor types [15-21], in vitro and in 
vivo. Likewise, over expression of a constitutively active 
p-STAT3 mutant has been found to induce tumor growth in 
murine and in vitro studies [22, 23]. Furthermore, STAT3 
has been shown to be a key regulator of tumor-mediated 
immune suppression [24, 25]. Xie et al. demonstrated that 
highly metastatic melanoma cell lines have higher levels of 
p-STAT3 than do poorly metastatic ones [26]. In addition, 
by blocking activated p-STAT3 in highly metastatic 
melanoma cells, the invasiveness and tumor growth were 
significantly suppressed. Consequently, metastases were 
able to be prevented in nude mice implicating p-STAT3 
in the development of distant metastasis [26]. Finally, 
p-STAT3 levels have been found to be higher in brain 
metastases than in cutaneous primary melanomas [14], 
further highlighting the possible role of p-STAT3 in the 
development of metastases, especially to the CNS. Thus, 
we hypothesized that higher systemic (non-CNS distant 
metastasis) tumor levels of p-STAT3 would predispose 
patients to the development of CNS metastasis and would 
be a negative prognostic factor for survival. 
MATERIALS AND METHODS
Ethics Statement
This study was conducted according to LAB09-
0463 approved by the Institutional Review Board of The 
University of Texas MD Anderson Cancer Center in which 
299 patients with stage IV melanoma were identified from 
the MD Anderson Cancer Center Melanoma Informatics, 
Tissue Resource, and Pathology Core (MelCore) database. 
Surviving patients provided their written consent for their 
clinical information to be stored in the MelCore database 
and the use of their tissue under LAB03-320 and LAB00-
063. Minors were not involved in this study.
Melanoma Tissue Microarray (TMA)
Patients included those with systemic, non-CNS 
metastasis samples accessioned at MDACC between 
1992 and 2010. Data entry was finalized on October 27, 
2011. The composition of the TMA consisted of resected 
metastasis from the lung (n = 155), intestine/colon (n = 79), 
liver (n = 18), adrenal gland (n = 13), spleen (n = 12), gall 
bladder (n = 5) and other non-CNS sites (n = 17). Of these 
patients, 148 had or developed radiographic confirmed 
CNS metastases. For TMA construction, two 1mm cores 
Figure 1: Immunohistochemical staining of melanoma 
tissue sections demonstrating p-STAT3 staining 
confined to the nucleus. Representative negative (A) and 
positive (B) specimens are shown (400x magnification).
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where obtained per tumor sample. The rationale for using 
a TMA was to facilitate analysis of the largest number of 
cases possible. The study neuropathologist (GNF) gathered 
the tissue sections and confirmed the tumor pathology by 
using the archived paraffin-blocked tissue sections. The 
time from resection to fixation was less than 20 minutes in 
all cases in accordance with the CLIA (Clinical Laboratory 
Improvement Amendments) standard.
Immunohistochemical analysis of p-STAT3 
expression
The method for detecting and determining p-STAT3 
expression has been previously described [27]. Briefly, 
formalin-fixed, paraffin-embedded 5µm sections of the 
melanoma TMA were first deparaffinized in xylene and 
rehydrated in ethanol. The endogenous peroxidase activity 
was blocked with 0.3% hydrogen peroxide/methanol for 
10 minutes at room temperature before antigen retrieval 
was begun. The ThermoScientific PT Module (Thermo 
Fisher Scientific, Fremont, CA) with citrate buffer (pH 6.0) 
was then used for antigen retrieval. After blocking with a 
serum-free protein block solution (DAKO, Carpinteria, 
CA), diluted anti-p-STAT3 (tyrosine705) antibody (1:50; 
Cell Signaling Technology, Danvers, MA) was added to 
the TMA and the specimens were incubated overnight 
in a humidified box at 4°C. The slides were then stained 
with a biotin-labeled secondary antibody (biotinylated 
link universal solution; DAKO) for 60 minutes at room 
temperature. Finally, streptavidin-horseradish peroxidase 
(DAKO) was added and incubated with the slides for 30 
minutes at room temperature. Diaminobenzidine (DAKO) 
was used as the chromogen, and color development was 
halted by dipping the slides in distilled water. The nuclei 
were then counterstained with hematoxylin. For the 
negative control, an isotype antibody was used (Santa 
Cruz Bio-technology, Santa Cruz, CA).
Quantification of p-STAT3 expression
Independent  observers  (IL,  SF)  quantitatively 
evaluated p-STAT3 expression by analyzing the cores 
using high-power fields (maximum: x40 objective and x10 
eyepiece) of each specimen (Fig. 1). These evaluations 
were validated by the study pathologist (GNF). The 
observers examined each sample in duplicate cores from 
different areas of the same tumor in a blinded fashion. 
Up to six observations were made of the metastatic 
tissue sample from each patient. For each observation, 
the total number of cells and the number of cells with 
positive p-STAT3 nuclear staining were counted. The 
percentage of p-STAT3 positive cells was then calculated 
for each observation. The average percentage of cells with 
positive p-STAT3 nuclear staining was calculated from all 
Figure 2: Box and whisker plots stratified by systemic organ metastasis site demonstrating p-STAT3 expression, as 
determined by immunohistochemical staining, among patients with stage IV melanoma (p = 0.0155 across all tissue 
types).
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observations for each patient’s sample. For most patients, 
this was the average of six sets of counts. Hereafter, this 
average percentage of p-STAT3-positive cells is referred 
to as the p-STAT3 expression level. Observations in which 
no cells could be counted were excluded. We minimized 
potential mismatching of the data by staining an intact 
TMA with hematoxylin and eosin and identifying the 
correct location of each tissue core by visually matching 
the tumors on the basis of their unique histologic elements. 
Statistical analysis
The Wilcoxon rank-sum test was used to compare 
the distribution of p-STAT3 expression between patients 
with and without CNS metastasis, and the Kruskal-Wallis 
test was used to compare the distribution of p-STAT3 
expression among tissue types. The tissue type denotes the 
organ from which the melanoma metastasis specimen was 
taken. Median survival was computed from the date of 
stage IV diagnosis to the date of the patient’s last known 
vital status. The time to first CNS metastasis was computed 
from the date of stage IV diagnosis to the date of first 
CNS metastasis. Patients with preceding CNS metastasis 
or CNS metastasis at the time stage IV diagnosis were 
excluded (n = 21). Patients that did not experience a CNS 
metastasis were censored by using the date of the patient’s 
last brain imaging assessment or the last date the patient 
was seen by a physician at MD Anderson Cancer Center. 
Kaplan-Meier survival curves were used to estimate 
survival [28], and the log-rank test was used to assess 
differences between groups of patients with different levels 
of p-STAT3 expression [29]. Cox proportional hazards 
regression was used to analyze the association between 
p-STAT3 expression and survival. Logistic regression 
was used to analyze the association between p-STAT3 
expression and the development of CNS metastasis. The 
p-STAT3 was considered first as a continuous variable, 
and secondary analyses were performed separately which 
categorized patients as having p-STAT3 expression < 1% 
vs. ≥ 1%. We decided on this dichotomization based on 
its possible clinical relevance after analyzing absolutely 
none versus any p-STAT3 expression as well as comparing 
percentiles that represented the highest and lowest levels 
of expression. Additionally, in the literature [30], it is 
acceptable to use a minimum percentage of expression 
as evidence of expression rather than dichotomizing 
based on zero. Because the distribution of p-STAT3 was 
positively skewed (median = 8.99%, range 0 - 74%), 
transformed expression values were analyzed but did not 
yield significantly different results and are not reported. A 
p-value of less than 0.05 was considered significant. All 
statistical analysis were performed using SAS software 
version 9.2 for Windows (SAS Institute, Cary, NC).
RESULTS
Study population
Tissue sections from 299 patients with distant 
metastatic melanoma were included in the TMA of which 
151 (51%) did not have CNS metastasis at the time of the 
last follow-up. The median age of the patients at initial 
diagnosis was 50 years (range: 12 – 80 years) and 56 
years at the time of the stage IV diagnosis (range: 13 – 
85 years). The majority were caucasian (95%) and male 
Figure 3: Kaplan-Meier survival estimates 
stratified  by  p-STAT3,  expression  determined  from 
immunohistochemical staining, in patients with stage 
IV melanoma. In melanoma patients stratified based by the 
amount of p-STAT3 expression <1% versus ≥1%, there was no 
significant difference in median survival time (p = 0.86; n = 63, 
236, respectively). 
Figure 4: Kaplan-Meier survival estimates of the 
overall probability of developing CNS metastasis from 
the time of the stage IV diagnosis. In patients stratified 
based on the amount of p-STAT3 expression, <1% versus ≥1%, 
in their systemic metastasis, there was no significant difference 
in time to development of CNS metastasis (p = 0.14; n = 55, 223, 
respectively).Oncotarget 2012; 3:  336-344 340 www.impactjournals.com/oncotarget
(71%). Figure 2 summarizes the overall composition of the 
melanoma TMA, which consisted of resected metastasis 
from the lung (n = 155), intestine/colon (n = 79), liver 
(n = 1 8), adrenal gland (n = 13), spleen (n = 12), gall 
bladder (n = 5) and other (n = 17). The most common 
site of melanoma metastasis was the lung, consistent 
with previous reports [31]. The distribution of p-STAT3 
expression was significantly different across all tissue 
types (p = 0.0155), with the highest expression seen in the 
lung (mean 16.5%, median 12.3%).
The expression of p-STAT3 does not impact 
overall survival in stage IV melanoma patients
Cox proportional hazard regression was used to 
determine whether p-STAT3 expression was a significant 
predictor of survival. For all stage IV melanoma patients, 
the overall median survival was 2.7 years. Intratumoral, 
nuclear p-STAT3 expression was not an independent 
univariate predictor of overall survival in stage IV 
melanoma patients (HR = 1.008; 95%CI: 0.998-1.015; n 
deaths = 222; p = 0.13) (Fig. 3). 
Because we had observed a statistically significant 
difference between p-STAT3 expression levels in 
melanoma metastasis of different tissue types, we 
conducted a sub-analysis of survival by tissue type using 
the two tissue types with the greatest number of samples. 
Patients with metastasis originating from the intestine 
and lung were selected to represent the higher and lower 
ends of the p-STAT3 spectrum, respectively. We found 
no  significant  differences  in  survival  in  patients  with 
metastasis to either of these tissue types based on the 
amount of p-STAT3 expression, validating our finding that 
p-STAT3 expression is not a prognostic marker in patients 
with stage IV melanoma.
The expression of p-STAT3 is not predictive of 
development or time to CNS metastasis 
Among the systemic melanoma metastasis of stage 
IV melanoma patients without CNS metastasis (n=151), 
p-STAT3 expression was 14.7% (SD = 14.6); whereas 
it was 13.3% (SD = 16.5) in the systemic melanoma 
metastasis of those patients with CNS metastasis (n=148). 
Although there was some evidence of a difference in the 
distribution of p-STAT3 by CNS metastasis status among 
these stage IV melanoma patients (p = 0.05); this small 
difference may not be clinically meaningful and may be 
attributable to the fact that there were more lung samples, 
which have higher p-STAT3 expression, in the group 
without CNS metastasis. Univariate logistic regression 
analysis revealed that p-STAT3 expression (when defined 
as a continuous variable) in systemic melanoma metastasis 
was not predictive for the development of CNS metastasis 
(HR: 0.994; 95% Wald CI: 0.980 – 1.009; n metastases = 
148; p = 0.44).
The median time to the development of CNS 
metastasis was 3.0 years from the time of the stage IV 
diagnosis. We found no significant differences in time 
Figure  5:  Kaplan-Meier  survival  estimates  of  the 
overall probability of survival from the time of the 
stage IV diagnosis. (A) The median survival was 1.9 years in 
those patients that developed CNS metastasis compared to 3.4 
years in those patients that did not. (B) In melanoma patients that 
developed CNS metastasis stratified by the amount of p-STAT3 
expression,  <1%  versus  ≥1%,  in  their  systemic  metastasis, 
no significant difference was found in survival (p = 0.37; n = 
40, 108, respectively). (C) In melanoma patients that did not 
develop  CNS  metastasis,  significant  difference  were  found 
in survival based on the amount of p-STAT3 expression, <1% 
versus ≥1%, in their systemic metastasis (p = 0.049; n = 23, 128, 
respectively). 
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to CNS metastasis based on the amount of p-STAT3 
expression in the systemic melanoma metastasis (Fig. 4). 
The expression of p-STAT3 in stage IV melanoma 
patients without CNS metastasis impacts survival
Since the presence of CNS metastasis has been 
previously demonstrated to be a negative prognostic 
factor for survival in stage IV melanoma patients, we 
evaluated this parameter within our dataset and validated 
this previously identified prognosticator (Fig. 5A; log-rank 
p < 0.001). The overall median survival was 1.9 years in 
those patients with CNS metastasis compared to 3.4 years 
in those patients who had not developed CNS metastasis. 
We further analyzed the association between p-STAT3 and 
overall survival separately by CNS metastasis status. No 
prognostic impact was found within the subset of patients 
that had developed CNS metastasis based on the systemic 
p-STAT3 expression (Fig. 5B). However, within the subset 
of patients without CNS metastasis, we found significant 
differences in survival based on p-STAT3 expression (Fig. 
5C) (HR = 1.871; 95%CI: 0.993 - 3.525; n deaths = 95; 
p = 0.05). 
DISCUSSION
Our study is the first to demonstrate the negative 
prognostic influence of p-STAT3 expression in stage IV 
melanoma patients that did not develop CNS metastasis 
but not in those patients that did develop CNS metastasis. 
These findings are consistent with those of a previously 
published study examining the negative impact of 
p-STAT3 on the progression of human cutaneous 
melanoma [32]. Our results are also consistent with the 
previously demonstrated prognostic influence of p-STAT3 
on survival in patients with other types of malignancies, 
such as glioma [27]. However, given the biological role of 
p-STAT3 in invasion, migration, and metastasis, we were 
surprised that p-STAT3 expression in systemic melanoma 
metastases was not associated with either the development 
of CNS metastasis or the time to first CNS metastasis. 
Furthermore, although we found differences in the 
p-STAT3 expression between different sites of metastasis, 
with the lung being the most common site [31], despite 
elevated p-STAT3 expression in the subset of patients with 
melanoma lung metastasis, these patients did not have a 
significantly higher risk of developing CNS metastasis.
Our secondary findings are in direct contrast with 
the results of a previous study, which demonstrated that 
p-STAT3 expression promotes CNS metastasis [14]. 
In that study, cloned human melanoma cell lines with 
enforced upregulation of constitutive STAT3 or blockade 
of STAT3 activity were evaluated for their ability to 
metastasize to the brain in murine models. In our study, 
the lack of an association between p-STAT3 expression 
and CNS metastasis may be attributed to the fact that the 
systemic tumor biology may not be reflective of the tumor 
microenvironment immediately preceding development of 
CNS metastasis. In fact, most of the systemic melanoma 
metastases that were resected and used in this analysis 
preceded the development of CNS metastasis by several 
years - ample opportunity for the biology to be altered. 
Another possible explanation for this discrepancy is the 
limitations of animal systems in recapitulating the biology 
of human melanoma patients. Ultimately, we suspect that 
the propensity to develop CNS metastasis is governed 
not by a single mechanism or pathway but rather by the 
combination and interaction of several key pathways and 
genes that ultimately influence outcome [33, 34]. 
Perhaps one of the more optimistic results of this 
study is the extended median survival time seen in stage 
IV melanoma patients, including those that developed 
CNS metastasis. In our analysis, the median survival time 
was 3.4 years in patients with stage IV melanoma that 
did not develop CNS metastasis (from the time of stage 
IV diagnosis), 1.9 years in those that developed CNS 
metastasis (from the time of stage IV diagnosis), and 1.0 
years from the date of diagnosis of CNS metastasis; these 
compare favorably with historical data, which found a 
median survival time of less than 1 year in all patients 
with disseminated melanoma [35] and of only 3.8 months 
in patients with brain metastasis [8]. The current analysis 
was conducted with samples from patients treated at 
a single institution, which pursues aggressive surgical 
and multimodality treatment of metastatic melanoma, 
including in patients with brain metastasis that could bias 
these results in a favorable manner. Other recent series 
at institutions that pursue similar treatment schemas 
have demonstrated similar outcomes, both in the setting 
of melanoma patients with brain metastases [36] and in 
melanoma patients with limited systemic metastases 
amenable to complete surgical resection [37]. Despite the 
still grim prognosis of metastatic melanoma, these findings 
are certainly encouraging.
Our  findings  also  inform  the  study  design  and 
stratification  for  planned  clinical  trials  of  p-STAT3 
inhibitors. The data presented here indicate that stage 
IV melanoma patients that do not have CNS metastasis 
should  be  stratified  on  the  presence  or  absence  of 
p-STAT3 expression during efficacy clinical trials. One 
small molecule inhibitor of p-STAT3 with excellent 
CNS penetration, WP1066, has demonstrated antitumor 
effects in a murine model of melanoma, including 
against melanoma within CNS [38]. The in vivo 
effects of WP0166 are accompanied by a reduction 
of immunosuppression, including regulatory T cells 
(Tregs) and tumor-supportive M2 macrophages, with a 
concomitant increase in the cytotoxic immune response 
of T cells. These findings highlight the likely importance 
of immune cells on the effects of p-STAT3 inhibitors on 
tumor activity but also suggest that activity of p-STAT3 in Oncotarget 2012; 3:  336-344 342 www.impactjournals.com/oncotarget
the immune cell populations may play a significant role 
in influencing outcome. STAT3 has been shown to be a 
key transcriptional regulator of FoxP3 in Tregs [39], and 
Treg infiltration has been shown in melanoma patients to 
be a negative prognosticator [40] and a predictor of local 
recurrence [41]. Furthermore, M2 macrophages defined by 
their expression of p-STAT3 [42-44] have also been shown 
to support angiogenesis and growth in melanoma [45] and 
may also be a prognostic factor in melanoma patients [46]. 
Given that the tumor-infiltrating immune cells constitute 
a small minority of the overall tumor population, a 
limitation of the current study is that this influential subset 
may have not been fully taken into account in the context 
of the overall p-STAT3 expression. 
In conclusion, as inhibitors of p-STAT3 move into 
clinical trials in patients with melanoma, including those 
with CNS metastasis, stratification by p-STAT3 should 
be considered for stage IV melanoma patients who have 
not developed CNS metastasis. Finally, given the current 
cumulative evidence, alterations in the clinical practice of 
surveillance brain magnetic resonance imaging need not 
be altered on the basis of p-STAT3 expression in systemic 
metastasis.
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